Earnings Call Insights: Daiichi Sankyo (OTCPK:DSKYF) Q3 2024 Management ViewRevenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven ...

Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer, ...

The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that the Food and Drug Administration has accepted and granted Priority Review to the supplemental Biologics ...

Enhertu is the primary driver of Daiichi’s revenue. For fiscal year 2024, Enhertu forecast is ¥539.9 billion (~$3.50 billion) in global revenue, up from ¥449 billion in FY2023 (see page 11, here).

Enhertu reduced the risk of disease progression or death by 36%, with a median PFS of 13.2 months versus 8.1 months for chemotherapy. The trial showed an ORR of 62.6% for Enhertu compared to 34.4% ...

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast ... discovered by Daiichi Sankyo DSNKY DSKYF and being jointly developed and commercialized by ...

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...